Press Release

Wanbury Limited Regd. Office: BSEL Tech Park, B- Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA Tel: +91-22-6794 2222 +91-22-7196 3222 CIN: L51900MH1988PLC048455 Email: info@wanbury.com Website: www.wanbury.com October 30, 2026 BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Dalal Street Bandra Kurla Complex, Mumbai – 400 001. Bandra (East), Mumbai -400 051. Script Code: 524212 Script Code: WANBURY Dear Sir/Madam, Sub.: Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under: Please find enclosed the press release regarding receipt of the Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening its Global Pharmaceutical Manufacturing Credentials. This is for your information and records. Thanking you. Yours faithfully, For Wanbury Limited Jitendra J. Gandhi Company Secretary Encl.: a/a US Europe Brazil Korea India Mexico Canada China WHO GMP PRESS RELEASE Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening its Global Pharmaceutical Manufacturing Credentials. Mumbai, 30 October 2026: Wanbury Limited is pleased to announce that its manufacturing facility at Tanuku, Andhra Pradesh, has successfully received the Good Manufacturing Practice (GMP) Compliance Certificate from Australia's Therapeutic Goods Administration (TGA), the regulatory authority responsible for therapeutic goods in Australia. The certification marks an important milestone in Wanbury's commitment to manufacturing excellence, stringent quality standards and strengthening its presence in regulated international pharmaceutical markets. Following a successful inspection conducted by the TGA on 8–9 June 2026, the Australian regulatory authority confirmed that the manufacturing facility complies with the applicable Good Manufacturing Practice requirements outlined in the PIC/S Guide to Good Manufacturing Practice for Medicinal Products. The certificate covers the manufacturing of the following six Active Pharmaceutical Ingredients (APIs): 1. Metformin Hydrochloride 2. Tramadol Hydrochloride 3. Sertraline Hydrochloride 4. Diphenhydramine Hydrochloride 5. Mefenamic Acid 6. Paroxetine Hydrochloride Hemihydrate The certificate was issued on 28 October 2026 and is valid until 9 December 2028, subject to the TGA's applicable re-inspection requirements. With this approval, the TGA will proceed with issuing GMP clearances to Australian sponsors associated with the manufacturing facility, enabling the necessary regulatory clearances for the supply of the approved APIs to the Australian market. A Step Forward in Global Growth This achievement reinforces Wanbury's focus on building globally compliant manufacturing capabilities and expanding its footprint across international markets. Recognition by a stringent regulatory authority such as Australia's TGA further strengthens the company's quality credentials and its ability to serve customers and partners in regulated pharmaceutical markets. The certification represents another significant milestone in Wanbury's journey towards operational excellence, regulatory compliance and sustainable business growth. US Europe Brazil Korea India Mexico Canada China WHO GMP About Wanbury Ltd: Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). The API product portfolio includes Antidiabetic, Antidepressant, Pain management, Antihistamine, Anti-inflammatory, Antidepressant and various other products in pipeline. The company's clients include some of the leading global generic players. In formulations, the company has a wide presence across major therapeutic categories like cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory, & analgesics. For more details on Wanbury Ltd.: https://www.wanbury.com/ For any Investor Relations query, please contact: Jitendra J. Gandhi Smit Shah / Hanishi Shah Company Secretary, Adfactors PR Wanbury Limited Oasis Complex, Kamala Mills Compound, BSEL Techpark,B' Wing, 10th Floor, City Hall, Pandurang Budhkar Marg, Sector 30-A,Opp. Vashi Railway Station, Lower Parel West, Mumbai – 400021 Vashi, Navi Mumbai - 400703, Tel : +91 9870789596 / +91 9619059339 Maharashtra, India. Email : smit.shah@adfactorspr.com / Tel: +91-22-6794 2222 hanishi.shah@adfactorspr.com Email: jitendra.gandhi@wanbury.com Caution Concerning Forward- Looking Statements: This document may contain statements, which reflect management’s current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments. US Europe Brazil Korea India Mexico Canada China WHO GMP